Forte Biosciences (NASDAQ:FBRX) Earns Buy Rating from Analysts at TD Cowen

TD Cowen began coverage on shares of Forte Biosciences (NASDAQ:FBRX – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating on the stock. Separately, Chardan Capital reissued a “buy” rating and set a $64.00 target price on shares of Forte Biosciences in a research […]

Leave a Reply

Your email address will not be published.

Previous post Performance Food Group (NYSE:PFGC) Price Target Raised to $96.00
Next post Freshworks (NASDAQ:FRSH) Cut to Underweight at Wells Fargo & Company